Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis

Blood Cancer J. 2021 Feb 8;11(2):18. doi: 10.1038/s41408-021-00416-4.

¹ Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA.
² Cytogenetics and Genomic Microarray Laboratory, ARUP Laboratories, Salt Lake City, UT, USA.
³ Center for Individualized Medicine-Biomarker Discovery, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁵ Division of Hematology, Oncology, and Transplantation, Department of Medicine and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
⁶ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
⁸ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁹ Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA. baughn.linda@mayo.edu.

^# Contributed equally.

No abstract available

Publication types